Precision Optics Reports First Quarter Fiscal Year 2021 Financial Results

Conference Call Scheduled for today, November 12, 2020 at 5:00pm ET

PR Newswire

GARDNER, Mass., Nov. 12, 2020 /PRNewswire/ — Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, announced operating results on an unaudited basis for its first quarter fiscal year ended September 30, 2020.

First quarter fiscal 2021 highlights:

  • Revenue for the quarter ended September 30, 2020 was $2.76 million compared to $2.51 million in the same quarter of the previous fiscal year, an increase of 10%; and up 23% sequentially compared to $2.24 million in the fourth quarter of the previous fiscal year.
  • Gross margins for the quarter ended September 30, 2020 of 35% compared to 39% in the same quarter of the prior year; and compared to 29% for the quarter ended June 30, 2020.
  • Net income of $763 during the quarter included $71,146 of stock-based compensation. This compared to a loss of $86,110 in the same quarter a year ago and loss of $323,085 in the fourth quarter of fiscal 2020.
  • The Company’s cash position remains strong with an ending balance for the first quarter of $900,510.

Precision Optics’ CEO, Joseph Forkey, commented, “I am pleased with the operating performance during the first quarter which included a return to revenue growth.  Our revenues grew sequentially by 23%, and by 10% year over year, as we saw a recovery in shipments on orders that had been delayed due to issues surrounding COVID-19 over the past few quarters. This growth in revenue, coupled with sequential improvement in gross margins and continued efficient management of expenses, lead to slight net income profitability and positive adjusted EBITDA. Importantly, our balance sheet remained strong with more than $900,000 in cash.”

Dr. Forkey concluded, “Our team continues to maintain a safe overall workplace for our employees while meeting the expectations and demands of our customers. Production disruptions resulting from COVID-19 related precautions created a slightly elevated backlog going into the quarter, which we have largely now delivered.  Importantly, COVID-19 did not materially alter end-market programs and we are seeing the progression of numerous pipeline projects that have the ability to be significant contributors to revenue over the next few quarters and years. We are still not out of the woods as it relates to the near term impacts from COVID-19 as customers work through excess inventory and evaluate the velocity of sell through of their end products in the market. However, the increase we have seen in pipeline projects as well as requests for quotation gives me optimism.  We continue to have confidence that our existing production programs will ultimately return to pre-pandemic levels and combined with new programs that are building today, we expect to have a larger base of revenue.  Our business today is inherently growing nicely.” 

The following table summarizes the first quarter (unaudited) results for the periods ended September 30, 2020 and 2019:

Three Months

Ended Sept 30,

2020

2019

Revenues

$  2,757,901

$  2,514,984

Gross Profit

975,178

974,117

Stock Compensation Expenses

59,913

110,272

Other

913,665

949,727

Total Operating Expenses

973,578

1,059,999

Operating Income (Loss)

1,600

(85,882)

Net Income (Loss)

793

(86,110)

Income (Loss) per Share

$            0.00

$          (0.01)

Basic and Diluted

Weighted Average Common Shares Outstanding

Basic and Diluted

13,191,789

12,832,389

Fully Diluted

13,684,233

12,832,389

Conference Call Details
The Company has scheduled a conference call to discuss the first quarter 2021 financial results for Thursday, November 12, 2020 at 5:00 p.m. ET.

Call-in Information: Interested parties can access the conference call by dialing (844) 735-3662 or (412) 317-5705.

Live Webcast Information: Interested parties can access the conference call via a live Internet webcast, which is available at https://www.webcaster4.com/Webcast/Page/2109/38482

Replay: A teleconference replay of the call will be available until November 19, 2020 at (877) 344-7529 or (412) 317-0088, confirmation # 10149688. A webcast replay will be available at https://www.webcaster4.com/Webcast/Page/2109/38482.  

About Precision Optics Corporation
Precision Optics Corporation has been a leading developer and manufacturer of advanced optical instruments since 1982. Using proprietary optical technologies, the Company designs and produces next generation medical instruments, Microprecision™ micro-optics with characteristic dimensions less than 1 millimeter, and other advanced optical systems for a broad range of customers including some of the largest global medical device companies. The Company’s innovative medical instrumentation line includes state-of-the-art endoscopes and endocouplers as well as custom illumination and imaging products for use in minimally invasive surgical procedures. The Company believes that current advances in its proprietary micro-optics and 3D imaging technologies present significant opportunities for expanding applications to numerous potential medical products and procedures. The Company’s website is www.poci.com. Investors can find Real-Time Quotes and market information for the Company on www.otcmarkets.com/stock/PEYE/quote.

About Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express the Company’s intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company’s future activities or future events or conditions. These statements are based on current expectations, estimates and projections about the Company’s business based, in part, on assumptions made by the Company’s management. These statements are not guarantees of future performances and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including those risks discussed in the Company’s annual report on Form 10-K and in other documents that we file from time to time with the SEC. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement, except as required by law.

Company Contact: 
PRECISION OPTICS CORPORATION
22 East Broadway
Gardner, Massachusetts 01440-3338
Telephone: 978-630-1800

Investor Contact:
LYTHAM PARTNERS, LLC
Robert Blum
Phoenix | New York
Telephone: 602-889-9700
[email protected]

Following are the Company’s Consolidated Balance Sheets at September 30, 2020 and June 30, 2020, and Statements of Operations, for the three month periods ended September 30, 2020 and 2019:


PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES


CONSOLIDATED BALANCE SHEETS


(UNAUDITED)


September 30,

2020


June 30,

2020


ASSETS

Current Assets:

Cash and cash equivalents

$

900,510

$

1,134,697

Accounts receivable (net of allowance for doubtful accounts of $249,200 at September 30, 2020 and $248,450 at June 30, 2020)

1,585,001

1,481,437

Inventories

2,138,390

2,197,244

Prepaid expenses

112,015

133,707

Total current assets

4,735,916

4,947,085

Fixed Assets:

Machinery and equipment

2,915,847

2,907,533

Leasehold improvements

754,438

731,801

Furniture and fixtures

178,640

178,640

3,848,925

3,817,974

Less—Accumulated depreciation and amortization

3,349,910

3,314,824

Net fixed assets

499,015

503,150

Operating lease right-to-use asset

104,380

118,403

Patents, net

104,887

95,229

Goodwill

687,664

687,664

TOTAL ASSETS

$

6,131,862

$

6,351,531


LIABILITIES AND STOCKHOLDERS’ EQUITY

Current Liabilities:

Current portion of capital lease obligation

$

33,047

$

51,761

Current portion of acquisition earn out liability

166,667

166,667

Note payable to bank

808,962

808,962

Accounts payable

1,022,803

1,066,005

Customer advances

206,665

417,059

Accrued compensation and other

578,723

581,770

Operating lease liability

58,136

57,156

Amount due for business acquisition

Total current liabilities

2,875,003

3,149,380

Capital lease obligation, net of current portion

33,582

35,810

Acquisition earn out liability

333,333

333,333

Operating lease liability

46,244

61,247

Stockholders’ Equity:

Common stock, $0.01 par value: 50,000,000 shares authorized; issued and outstanding – 13,191,789 shares at September 30, 2020 and June 30, 2020

131,918

131,918

Additional paid-in capital

49,774,132

49,702,986

Accumulated deficit

(47,062,350)

(47,063,143)

Total stockholders’ equity

2,843,700

2,771,761

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

$

6,131,862

$

6,351,531

 


PRECISION OPTICS CORPORATION, INC. AND SUBSIDIARIES


CONSOLIDATED STATEMENTS OF OPERATIONS


FOR THE THREE MONTHS ENDED


SEPTEMBER 30, 2020 AND 2019


(UNAUDITED)


Three Months

Ended September 30,


2020


2019

Revenues

$

2,757,901

$

2,514,984

Cost of Goods Sold

1,782,723

1,540,867

Gross Profit

975,178

974,117

Research and Development Expenses, net

151,576

152,154

Selling, General and Administrative Expenses

822,002

907,845

Total Operating Expenses

973,578

1,059,999

Operating Income (Loss)

1,600

(85,882)

Interest Expense

(807)

(228)

Net Income (Loss)

$

793

$

(86,110)

Income (Loss) Per Share:

Basic and Fully Diluted

$

0.00

$

(0.01)

Weighted Average Common Shares Outstanding:

Basic

13,191,789

12,832,389

Fully Diluted

13,684,233

12,832,389

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/precision-optics-reports-first-quarter-fiscal-year-2021-financial-results-301172347.html

SOURCE Precision Optics Corporation

Houston American Energy Corp. Announces Management Changes

PR Newswire

HOUSTON, Nov. 12, 2020 /PRNewswire/ — Houston American Energy Corp. (NYSE American: HUSA) today announced certain management changes.

James Schoonover, the company’s President and Chief Executive Officer, has advised the company that he would be stepping down from those positions, effective December 1, 2020.  Mr. Schoonover joined the company’s board in April 2018 and assumed the roles of Interim President and Chief Executive Officer in June 2018.  Mr. Schoonover will continue to serve as a director of the Company.

The company’s board of directors has selected John Terwilliger to resume his prior roles as President and Chief Executive Officer of the company, effective upon Mr. Schoonover’s resignation on December 1, 2020.  Mr. Terwilliger will also join the company’s board as a director effective December 1, 2020.

Steve Hartzell, Chairman of Houston American Energy, stated, “We are grateful for Jim’s stepping up to fill the interim CEO role and for his service beyond the period we initially anticipated.  Jim has been a steady hand and we are pleased that he will continue to provide valuable insights in his ongoing role on the board.

With John Terwilliger’s return to the CEO role, we gain a seasoned leader with many years of industry experience and a deep and unmatched understanding of our assets, operations and opportunities in our principal markets.”

About Houston American Energy Corp.

Based in Houston, Texas, Houston American Energy Corp. is a publicly-traded independent energy company with interests in oil and natural gas wells, minerals and prospects. The Company’s business strategy includes a property mix of producing and non-producing assets with a focus on the Permian Basin in Texas, Louisiana and Colombia.

For additional information, view the company’s website at www.houstonamerican.com or contact Houston American Energy Corp. at (713) 222-6966.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/houston-american-energy-corp-announces-management-changes-301172366.html

SOURCE Houston American Energy Corp.

Cogent Biosciences to Present at Jefferies 2020 Virtual London Healthcare Conference

PR Newswire

CAMBRIDGE, Mass., Nov. 12, 2020 /PRNewswire/ — Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, Chief Executive Officer and President, will present a corporate overview at the Jefferies 2020 Virtual London Healthcare Conference taking place November 17 – 19, 2020. 

A recording of the presentation will be available to view after the conference under the “Events” tab on the investor relations section of the Cogent Biosciences website at: https://investors.cogentbio.com/events.

About Cogent Biosciences, Inc. 
Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, PLX9486, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. Cogent Biosciences is headquartered in Cambridge, MA. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, pertaining to the company’s planned participation at an investor conference, which may include discussion of the company’s business and operations; projected cash runways; future product development plans; upcoming results from clinical trials including from its lead program, PLX9486. The use of words such as, but not limited to, “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our clinical results and other future conditions. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. We may not actually achieve the forecasts disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in Cogent Biosciences’ most recent Annual Report on Form 10-K filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither we, nor our affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cogent-biosciences-to-present-at-jefferies-2020-virtual-london-healthcare-conference-301172210.html

SOURCE Cogent Biosciences, Inc.

BetMGM Hires Andrew Hagopian as Chief Legal Officer

Hagopian Adds World-Class Legal Expertise as Company Continues Expansion

PR Newswire

JERSEY CITY, N.J., Nov. 12, 2020 /PRNewswire/ — BetMGM, a leading sports betting and digital gaming entertainment company, today announced Andrew Hagopian will join BetMGM’s executive team as Chief Legal Officer. Hagopian will oversee the company’s legal and compliance departments and will report to BetMGM’s CEO, Adam Greenblatt.

Most recently, Hagopian was Chief Corporate Counsel of MGM Resorts International, where he was instrumental in the collaboration with GVC Holdings to establish BetMGM in 2018. At MGM Resorts, Hagopian led a team of attorneys and other professionals responsible for legal aspects of gaming regulatory matters, property operations, joint ventures, corporate transactions, sports and entertainment, development, intellectual property, data privacy, corporate governance, securities, finance and enterprise contracts.

“BetMGM resides at the intersection of technology and gaming,” said Hagopian. “This is an exciting opportunity to leverage my industry and transactional experience at a fast-moving company in a complex, regulated environment where a strong continued commitment to excellence in compliance will be essential to our success.” 

Adam Greenblatt, CEO, BetMGM said, “Andrew’s deep industry experience, and proven ability to build and lead a world-class legal team, will serve BetMGM well as we continue to grow rapidly in a dynamic industry.”

Prior to MGM Resorts, Hagopian was an attorney with Gibson Dunn, a top-tier international law firm representing many Fortune 100 companies. At the firm, he was a member of the corporate transactions and securities practice group, negotiated complex M&A transactions and advised public companies on governance and securities law matters.

Hagopian holds a J.D. from the Georgetown University Law Center and a B.S. in Business Administration from the University of Southern California Marshall School of Business.

For more information, follow @BetMGM on Twitter.


ABOUT BETMGM

BetMGM is a market leading sports betting and digital gaming entertainment company, pioneering the online gaming industry. Born out of a partnership between MGM Resorts International (NYSE: MGM) and GVC Holdings Plc (LSE: GVC), BetMGM has exclusive access to all of MGM’s U.S. land-based and online sports betting, major tournament poker, and online gaming businesses. Utilizing GVC’s US-licensed state of the art technology, BetMGM offers sports betting and online gaming via market leading brands including BetMGM, Borgata Casino, Party Casino and Party Poker. For more information, visit http://www.betmgminc.com/.

Statements in this release that are not historical facts are “forward-looking” statements and “safe harbor statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and/or uncertainties, including BetMGM’s ability to grow in new or existing jurisdictions. Management has based forward-looking statements on current expectations and assumptions and not on historical facts. Among the important factors that could cause actual results to differ materially from those indicated in such forward-looking statements include the effects of economic and market conditions in the jurisdictions in which BetMGM operates, competition with other iGaming and sports betting platforms, the timing and costs of expanding in new jurisdictions as well as obtaining and maintaining the required permits, licenses, financings, approvals and other contingencies in connection with growth in new or existing jurisdictions. In providing forward-looking statements, BetMGM is not undertaking any duty or obligation to update these statements publicly as a result of new information, future events or otherwise, except as required by law. If BetMGM updates one or more forward-looking statements, no inference should be drawn that it will make additional updates with respect to those other forward-looking statements.


MEDIA CONTACT


BetMGM

Elisa Richardson

[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/betmgm-hires-andrew-hagopian-as-chief-legal-officer-301171686.html

SOURCE MGM Resorts International

Boulder Growth & Income Fund, Inc. Declares Quarterly Distribution

PR Newswire

DENVER, Nov. 12, 2020 /PRNewswire/ — Boulder Growth & Income Fund, Inc. (NYSE: BIF) (the “Fund”) announced the declaration of the Fund’s quarterly distribution of $0.102 per share to occur in January 2021.  This distribution is being paid as part of BIF’s managed distribution program under which BIF will make per share distributions of $0.102 per quarter, or approximately $0.408 per year.  As of market close on November 6, 2020, the distribution amounts to approximately 4.15% of market price and 3.35% of net asset value (“NAV”) on an annualized basis. 

Due to the current discount of the Fund’s market price to its per share NAV, and the fact that distributions are made in cash (i.e., at NAV), if Fund shares continue to trade at a discount at the time of this distribution, then it will be accretive to BIF’s market-price-based return.  The January 2021 quarterly distribution will be payable in cash to stockholders of record per the following critical dates:


Pay Date


Record Date


Ex-Dividend Date


Amount Per Share

January 29, 2021

January 22, 2021

January 21, 2021

$0.102

As previously announced, the Board of Directors instituted a managed distribution program in accordance with its Section 19(b) exemptive order in November 2015.  In adopting the program, the Fund seeks to provide a regular quarterly distribution to its common stockholders which is not dependent on the amount of income earned or capital gains realized by the Fund.   

Investors should not make any conclusions about the Fund’s investment performance from the amount of the Fund’s distributions or the Fund’s distribution policy. With each distribution that does not consist solely of net investment income, the Fund will issue a notice to shareholders and an accompanying press release that will provide detailed information regarding the amount and composition of the distribution and other related information. The amounts and sources of distributions reported in the notice to shareholders are only estimates and are not being provided for tax reporting purposes. The actual amounts and sources of the amounts for tax reporting purposes will depend upon the Fund’s investment experience during its full fiscal year and may be subject to changes based on tax regulations. The Fund will send shareholders a Form 1099-DIV for the calendar year that will tell them how to report these distributions for federal income tax purposes.

_______________

The Fund

Boulder Growth & Income Fund, Inc. is a non-diversified closed-end investment company traded on the New York Stock Exchange under the trading symbol “BIF”. As of November 6, 2020, the Fund’s NAV was $12.18 per share and the closing market price was $9.82 (a 19.38% discount to NAV). For more information on the Fund, please visit the Fund’s webpage at www.bouldercef.com.

The Fund is a closed-end fund and does not continuously issue stock for sale as open-end mutual funds do. The Fund now trades in the secondary market. Investors wishing to buy or sell stock need to place orders through an intermediary or broker. The share price of a closed-end fund is based on the market value.

_______________

About SS&C | ALPS Advisors

ALPS Advisors, Inc., a wholly-owned subsidiary of SS&C Technologies, Inc., is a leading provider of investment products for advisors and institutions. With over $12 billion in assets under management as of September 30, 2020, the firm provides access to asset classes and boutique asset managers in real assets, alternatives, thematic/factor and fixed income through both ETF and open-end mutual fund structures. For more information, visit www.alpsfunds.com.

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. Some 18,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.

Rocky Mountain Advisers, LLC

RMA is an investment adviser registered with the SEC based out of Kansas.  More information about RMA is available at www.bouldercef.com as well as the SEC’s investment adviser search website at www.adviserinfo.sec.gov.

ALPS Portfolio Solutions Distributor, Inc., FINRA Member.                                                                                                            

NOT FDIC INSURED | May Lose Value | No Bank Guarantee

 

 

                                                                                                                                               

Cision View original content:http://www.prnewswire.com/news-releases/boulder-growth–income-fund-inc-declares-quarterly-distribution-301171299.html

SOURCE Boulder Growth & Income Fund, Inc.

Empire State Realty Trust Completes $180 Million Mortgage Financing

Empire State Realty Trust Completes $180 Million Mortgage Financing

NEW YORK–(BUSINESS WIRE)–
Empire State Realty Trust, Inc. (NYSE: ESRT) (the “Company”) today announced that it has closed on a $180 million mortgage loan for 250 West 57th Street, a 542,000 square foot Manhattan office and retail property. The new interest-only loan bears a fixed rate of 2.83% and matures in December 2030.

“We are pleased to close on this financing transaction,” said Christina Chiu, Empire State Realty Trust’s EVP and Chief Financial Officer. “The strong execution reinforces the quality of ESRT’s assets and our ability to access the capital markets.”

The Company will use the proceeds from the loan to bolster its liquidity and balance sheet flexibility. The loan was arranged by Estreich & Company.

About Empire State Realty Trust

Empire State Realty Trust, Inc. (NYSE: ESRT) owns, manages, operates, acquires and repositions office and retail properties in Manhattan and the greater New York metropolitan area, including the Empire State Building, the “World’s Most Famous Building.” ESRT is a leader in energy efficiency in the built environment and sustainability, and is the first commercial real estate portfolio in the U.S. to achieve the WELL Health-Safety Rating, an evidence-based, third-party verified rating for all facility types, focused on operational policies, maintenance protocols, emergency plans and stakeholder education to address a COVID-19 environment now and broader health and safety-related issues into the future. The Company’s office and retail portfolio covers 10.1 million rentable square feet, as of September 30, 2020, consisting of 9.4 million rentable square feet in 14 office properties, including nine in Manhattan, three in Fairfield County, Connecticut, and two in Westchester County, New York; and approximately 700,000 rentable square feet in the retail portfolio.

Investors

Empire State Realty Trust Investor Relations

(212) 850-2700

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Industrial Logistics Properties Trust to Present at Nareit’s REITworld: 2020 Annual Conference on Tuesday, November 17th

Industrial Logistics Properties Trust to Present at Nareit’s REITworld: 2020 Annual Conference on Tuesday, November 17th

NEWTON, Mass.–(BUSINESS WIRE)–Industrial Logistics Properties Trust (Nasdaq: ILPT) today announced that President John Murray, Chief Financial Officer Rick Siedel and Chief Operating Officer Yael Duffy will be presenting at Nareit’s REITworld: 2020 Annual Conference on Tuesday, November 17, 2020 at 11:30 a.m. Eastern Time.

To access the Company’s live presentation, please complete the complimentary registration for the conference at the following link: Nareit’s REITworld Registration. An on-demand recording will be available in the REITweek virtual environment for the remainder of the conference.

Industrial Logistics Properties Trust is a real estate investment trust, or REIT, that owns and leases industrial and logistics properties throughout the United States. ILPT is managed by the operating subsidiary of The RMR Group Inc. (Nasdaq: RMR), an alternative asset management company that is headquartered in Newton, MA.

Warning Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon ILPT’s present beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond ILPT’s control. For example, the Company’s presentation may be rescheduled to a different date or time or cancelled due to scheduling conflicts or other reasons. Investors are cautioned not to place undue reliance upon any forward-looking statements. Except as required by law, ILPT does not intend to update or change any forward-looking statements as a result of new information, future events or otherwise.

A Maryland Real Estate Investment Trust with transferable shares of beneficial interest listed on the Nasdaq.

No shareholder, Trustee or officer is personally liable for any act or obligation of the Trust.

Kevin Barry, Manager, Investor Relations

(617) 658-0776

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: REIT Finance Professional Services Commercial Building & Real Estate Construction & Property

MEDIA:

Logo
Logo

Diversified Healthcare Trust to Present at Nareit’s REITworld: 2020 Virtual Investor Conference on Tuesday, November 17th

Diversified Healthcare Trust to Present at Nareit’s REITworld: 2020 Virtual Investor Conference on Tuesday, November 17th

NEWTON, Mass.–(BUSINESS WIRE)–Diversified Healthcare Trust (Nasdaq: DHC) today announced that President and Chief Operating Officer Jennifer Francis, Chief Financial Officer and Treasurer Richard Siedel will be presenting at Nareit’s REITworld: 2020 Virtual Investor Conference on Tuesday, November 17, 2020 at 1:45 p.m. Eastern Time.

To access the Company’s live presentation, please complete the complimentary registration for the conference at the following link: Nareit’s REITworld Registration. An on-demand recording will be available in the REITworld virtual environment for the remainder of the conference.

Diversified Healthcare Trust (Nasdaq: DHC) is a real estate investment trust (REIT) focused on owning high-quality healthcare properties located throughout the United States. DHC seeks diversification across the health services spectrum: by care delivery and practice type, by scientific research disciplines, and by property type and location. As of September 30, 2020, DHC’s $8.2 billion portfolio included 407 properties in 37 states and Washington, D.C., occupied by more than 600 tenants, and totaling approximately 12 million square feet of medical office and life science properties and more than 30,000 living units. DHC is managed by the operating subsidiary of The RMR Group Inc., an alternative asset management company that is headquartered in Newton, MA. To learn more about DHC, visit www.dhcreit.com.

Warning Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements are based upon DHC’s present beliefs and expectations, but these statements and the implications of these statements are not guaranteed to occur and may not occur for various reasons, some of which are beyond DHC’s control. For example, the Company’s presentation may be rescheduled to a different date or time or cancelled due to scheduling conflicts or other reasons. Investors are cautioned not to place undue reliance upon any forward-looking statements. Except as required by law, DHC does not intend to update or change any forward-looking statements as a result of new information, future events or otherwise.

Michael Kodesch, Director, Investor Relations

(617) 796-8234

www.dhcreit.com

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Nursing Health Hospitals Physical Therapy Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update

Cortexyme Announces Third Quarter 2020 Financial Results and Provides Business Update

— GAIN Trial enrollment complete with 643 participants

— GAIN Trial interim analysis on schedule to complete in December 2020

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–
Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, today announced financial results for the third quarter 2020 and provided an update on its business.

“We are pleased with the strong participation in the GAIN Trial and deeply appreciate the support and dedication of patients and the medical community as we approach the interim analysis before the end of this year,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair. “With a strong balance sheet and a talented team, we remain confident that Cortexyme is well positioned to advance new therapeutic options for patients with Alzheimer’s and other degenerative diseases.”

GAIN Trial Updates: Evaluating Atuzaginstat, a New Potential Therapy for Alzheimer’s Disease

  • The Phase 2/3 GAIN Trial of atuzaginstat (COR388) in mild to moderate Alzheimer’s disease (AD) enrolled on time with final enrollment of 643 participants. Target enrollment was exceeded by approximately 12% in light of uncertainties which may be created by the global pandemic. Strong demand allowed the incremental enrollment to occur within projected timelines.
  • Cortexyme remains on track to conduct an interim analysis in the GAIN Trial in December 2020. Management will remain blinded to the interim analysis, which is being conducted by an independent Data Monitoring Committee (DMC). This interim analysis will be conducted after approximately 100 participants in each of the GAIN Trial’s three arms reach 24 weeks of treatment. The co-primary endpoints for the GAIN Trial’s interim analysis are change from baseline in ADAS-Cog11 and CDR-SB versus placebo. The four possible recommendations from the DMC after the interim analysis, and the only information that will be conveyed to management, are:

    • End the study early for overwhelming efficacy on either dose of atuzaginstat vs. placebo on the co-primary endpoints p< 0.005
    • Continue as planned
    • Increase sample size by up to 100 participants/arm based on favorable trends
    • End the study early for overwhelming futility, placebo vs. atuzaginstat p<0.05
  • A research abstract on the design of the GAIN Trial and its baseline biomarkers was the subject of an oral presentation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference on November 5, 2020. The presentation, “Phase 2/3 GAIN trial of atuzaginstat (COR388), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease: Update and baseline data,” highlights key biomarker data for the first 40-50% of participants in the GAIN Trial. All patient samples analyzed to date had evidence of P. gingivalis IgG in serum at baseline indicating immune response to systemic P. gingivalis infection, with 72% showing very high levels associated with higher infection and more severe periodontal disease. Additionally, the vast majority of subjects showed CSF biomarkers consistent with recently defined cutoffs for Alzheimer’s disease including amyloid β (Aβ) 42/40 ratio, tau and p-tau. As expected, 65% of the study participants are ApoE4 carriers who have been stratified across the three treatment groups. These data further reinforce the gingipain hypothesis and the design of the GAIN Trial to enroll the appropriate population for testing atuzaginstat.

Scientific Updates: Generating New Evidence and Expanding Our Pipeline

As atuzaginstat advances through late-stage clinical development, Cortexyme and external collaborators continue to present and publish new research and study data to advance the gingipain hypothesis for Alzheimer’s pathogenesis and identify additional development opportunities. Recent scientific presentations and research accomplishments are the following.

  • Cortexyme scientists presented new data in a poster at the Society for Immunotherapy of Cancer’s (SITC) 35th Anniversary Annual Meeting on November 9, 2020 entitled “PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat.” P. gingivalis has been linked to oral, esophageal, gastrointestinal, and pancreatic cancer and there is accumulating evidence that bacterial presence is correlated with worse disease prognosis. This study demonstrated that PD-L1 expression is increased by P. gingivalis infection in an esophageal cell line and this induction is blocked by either the lysine gingipain inhibitor atuzaginstat or an arginine gingipain inhibitor COR613. Infection resulted in nuclear β-catenin and disruption of the Wnt pathway complex regulating β-catenin function, and this is also blocked by gingipain inhibition. Tumor immune evasion markers PD-L1, PD-L2, and CTLA4 ligand CD80 were also induced by Pg infection on primed M2 macrophages, further supporting a role for Pg infection in blocking functional tumor immune surveillance.
  • COR588, a novel lysine gingipain inhibitor from Cortexyme’s library, remains on track with IND-enabling studies. Clinical studies are expected to begin in Q3 2021.
  • Cortexyme completed additional screening of its proprietary library of small molecules for a possible treatment for coronaviruses. The Company has identified inhibitors of the 3CL protease of SARS-CoV-2 and other coronaviruses in its library of small molecules which block viral replication in cells. Cortexyme is now proceeding to in vivo efficacy and toxicology testing.

Financial Results for the Quarter Ended September 30, 2020

Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents, and short and long-term marketable securities as of September 30, 2020, were $197.9 million, and includes approximately $117.6 million of net proceeds raised in Cortexyme’s private placement offering completed in February 2020. Cortexyme expects current cash, cash equivalents and marketable securities will be sufficient to fund its operating and capital expenditures through 2022 and the completion of the GAIN Trial.

Research and Development (R&D) Expenses: For the quarter ended September 30, 2020, R&D expenses were $17.0 million, primarily due to costs related to the research and development of atuzaginstat and the GAIN Trial.

General and Administrative (G&A) Expenses: For the quarter ended September 30, 2020, G&A expenses were $4.9 million. The expense was primarily attributable to personnel-related expenses, insurance, professional and legal fees, and stock-based compensation.

Net Loss: For the quarter ended September 30, 2020, net loss was $21.5 million, or a loss of $0.73 per basic share. Weighted average shares outstanding for the quarter ended September 30, 2020 was 29,488,739.

About Cortexyme, Inc.

Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.

Forward-Looking Statements

Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the translation to human of pre-clinical data, the pre-clinical results for our product candidates, the timing and success of our clinical trials and related data including the outcome of the interim analysis, the potential of atuzaginstat to treat Alzheimer’s disease and the potential therapeutic application in oncology, our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on November 12, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.

Cortexyme, Inc. Condensed Statements of Operations

(Unaudited)

(In thousands, except per share amounts)

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

2020

 

2019

 

2020

 

2019

Operating expenses:

Research and development

$

16,983

 

 

$

8,253

 

 

$

45,450

 

 

$

20,187

 

General and administrative

 

4,929

 

 

 

2,316

 

 

 

12,591

 

 

 

6,032

 

Total operating expenses

 

21,912

 

 

 

10,569

 

 

 

58,041

 

 

 

26,219

 

Loss from operations

 

(21,912

)

 

 

(10,569

)

 

 

(58,041

)

 

 

(26,219

)

Interest income

 

406

 

 

 

711

 

 

 

1,747

 

 

 

1,618

 

Net loss

 

(21,506

)

 

 

(9,858

)

 

 

(56,294

)

 

 

(24,601

)

Other comprehensive income / (loss):

 

 

 

 

 

 

 

Unrealized gain / (loss) on available for sales securities

 

(198

)

 

 

16

 

 

 

453

 

 

 

145

 

Total comprehensive loss

$

(21,704

)

 

$

(9,842

)

 

$

(55,841

)

 

$

(24,456

)

Net loss per share – basic and diluted

$

(0.73

)

 

$

(0.37

)

 

$

(1.94

)

 

$

(1.59

)

Cortexyme, Inc. Condensed Balance Sheets

(Unaudited)

(In thousands)

September 30, 2020 December 31, 2019

ASSETS

Current assets:

Cash and cash equivalents

$

64,246

 

$

51,214

Short term investments

 

73,548

 

 

48,650

Prepaid expenses and other current assets

 

5,180

 

 

6,192

Total current assets

 

142,974

 

 

106,056

Property and equipment, net

 

500

 

 

709

Operating lease right-of-use assets, net

 

848

 

 

625

Long term investments

 

60,133

 

 

16,763

Other assets

 

209

 

 

217

Total assets

$

204,664

 

$

124,370

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

4,309

 

$

3,075

Accrued expenses and other current liabilities

 

12,100

 

 

5,817

Total current liabilities

 

16,409

 

 

8,892

Long-term operating lease liability

 

244

 

 

Total liabilities

 

16,653

 

 

8,892

Total stockholders’ equity

 

188,011

 

 

115,478

Total liabilities and stockholders’ equity

$

204,664

 

$

124,370

 

Investor Contact:

Chris Lowe

Cortexyme, Inc.

Chief Financial Officer

[email protected]

Media Contact:

Hal Mackins

For Cortexyme, Inc.

[email protected]

(415) 994-0040

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Infectious Diseases FDA Seniors Dental Clinical Trials Biotechnology Health Consumer Pharmaceutical

MEDIA:

Logo
Logo

Revlon Reports Third Quarter Results

Revlon Reports Third Quarter Results

Previously-Announced Exchange Offer and Consent Solicitation Expected to Successfully Close

Quarterly Results Reflect Sequential Improvement in Top-Line COVID-19 Impacts and Continued Cost Reductions from the Company’s Restructuring Program

NEW YORK–(BUSINESS WIRE)–
Revlon, Inc. (NYSE: REV) today announced its results for the quarter ended September 30, 2020.

Quarter ended September 30, 2020 summary developments:1

  • As Reported net sales were $477.1 million in the third quarter of 2020, compared to $596.8 million during the prior-year period, a decline of 20.1%. E-commerce net sales increased approximately 13% versus the prior-year period and represented approximately 12% of third quarter 2020 net sales, versus approximately 9% in the prior-year period. As Reported net sales include approximately $119 million of estimated negative impacts associated with the ongoing and prolonged COVID-19 pandemic. Excluding the COVID-19 impacts, net sales were essentially flat compared to the prior-year period.
  • As Reported operating loss was $9.7 million in the third quarter of 2020, compared to $16.7 million of operating income during the prior-year period, driven primarily by the lower net sales described above and lower gross profit margin, driven in part by the adverse effects of the COVID-19 pandemic, including the negative impact from sales mix and higher manufacturing overhead absorption costs. These negative impacts were partially offset by $54.7 million in lower selling, general and administrative expenses, driven in part by cost reductions associated with the Company’s restructuring programs and additional actions specifically implemented to mitigate the adverse impact of the COVID-19 pandemic on the Company’s operating results. Adjusted operating income in the third quarter of 2020 decreased by $11.3 million to $14.3 million from $25.6 million in the prior-year period.
  • As Reported net loss was $44.5 million in the third quarter of 2020, versus a $44.7 million net loss in the prior-year period. The slightly lower net loss was driven primarily by a $31.2 million gain on the early extinguishment of Product’s Corporation’s 5.75% Senior Notes as a result of the Company’s repurchase and cancellation of approximately $44.4 million in principal face amount of Senior Notes during the third quarter of 2020, as well as a $17.4 million favorable foreign currency impact versus the prior-year period. These impacts were partially offset by the higher operating loss described above and $18.5 million in higher interest expense.
  • Adjusted EBITDA(a) in the third quarter of 2020 was $54.5 million versus $68.4 million in the prior-year period, with the decrease driven primarily by the lower net sales and lower adjusted gross profit margin attributed to the COVID-19 pandemic, partially offset by lower SG&A expenses.
  • As of September 30, 2020, the Company had total liquidity of $340.4 million.
  • As previously announced, all conditions precedent to the consummation of the Company’s Exchange Offer and Consent Solicitation have been satisfied and settlement is expected to occur on Friday, November 13, 2020, subject to customary closing conditions.

“While COVID-19 continues to have a significant impact on both the beauty industry overall as well as on our business, I am pleased that our third quarter 2020 results reflected a sequential improvement in our net sales decline versus the prior quarter. We remain diligent in managing our cost base to reduce COVID-19’s impact on our profitability. During the third quarter, the Company made further progress in expanding its e-commerce business, which now represents approximately 12% of the Company’s total net sales exceeding our expectations. Also, based on the aggregate principal amount of 5.75% Senior Notes tendered into the Company’s pending Exchange Offer, the Company expects to close that transaction later this week, giving us the additional runway needed to further execute on our business strategy, including investing in the brands and markets where we have scale, and growing our e-commerce business. We would like to thank all of our stakeholders for their support during the transaction. While we still have challenges to face – namely the ongoing impact of the COVID-19 pandemic – we believe we have the right long-term strategy in place and will continue to execute against it,” said Debra Perelman, Revlon’s President and Chief Executive Officer.

1 The results discussed include the following measures: U.S. GAAP (“As Reported”); and non-GAAP (“Adjusted”), which excludes certain Non-Operating Items and EBITDA Exclusions (as defined in Footnote (a)) from As Reported results. See footnote (a) for further discussion of the Company’s Adjusted measures. Reconciliations of As Reported results to Adjusted results are provided as an attachment to this release. In addition, where indicated, the Company analyzes and presents its results excluding the impact of foreign currency translation (“XFX”). Unless otherwise noted, the discussion is presented on an As Reported basis.

Third Quarter 2020 Results

Total Company Results

In calculating Adjusted results, adjustments were made for the Non-Operating Items and the EBITDA Exclusions in the case of Adjusted EBITDA, in each case as described in footnote (a).

 

 

Three Months Ended September 30,

(Unaudited)

 

 

2020

 

2019

 

As

Reported

 

Adjusted

(*)

(USD millions, except per share data)

 

As

Reported

 

Adjusted

(*)

 

As

Reported

 

Adjusted (*)

 

% Change

 

% Change

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

$

477.1

 

 

$

477.1

 

 

$

596.8

 

 

$

596.8

 

 

(20.1

)%

 

(20.1

)%

Gross Profit

 

242.8

 

 

248.4

 

 

327.8

 

 

329.0

 

 

(25.9

)%

 

(24.5

)%

Gross Margin

 

50.9

%

 

52.1

%

 

54.9

%

 

55.1

%

 

-400bps

 

-300bps

Operating (Loss) Income

 

$

(9.7

)

 

$

14.3

 

 

$

16.7

 

 

$

25.6

 

 

(158.1

)%

 

(44.1

)%

Net Loss

 

(44.5

)

 

(30.8

)

 

(44.7

)

 

(37.5

)

 

0.4

%

 

17.9

%

Adjusted EBITDA

 

 

 

54.5

 

 

 

 

68.4

 

 

 

 

(20.3

)%

Diluted Loss per Common Share

 

$

(0.83

)

 

$

(0.58

)

 

$

(0.84

)

 

$

(0.71

)

 

1.2

%

 

18.3

%

(*) Refer to footnote (a) to this Earnings Release for a discussion and reconciliation of the Company’s non-GAAP measures, including Adjusted Net Sales, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income (Loss), Adjusted Net Income (Loss), Adjusted EBITDA and Adjusted Diluted Loss per Common Share.

Segment Results

The Company operates in four reporting segments: Revlon; Elizabeth Arden; Portfolio; and Fragrances:

Revlon – The Revlon segment is comprised of the Company’s flagship Revlon brands. Revlon segment products are primarily marketed, distributed and sold in the mass retail channel, large volume retailers, chain drug and food stores, chemist shops, hypermarkets, general merchandise stores, e-commerce sites, television shopping, department stores, professional hair and nail salons, one-stop shopping beauty retailers and specialty cosmetic stores in the U.S. and internationally under brands such as Revlon in color cosmetics; Revlon ColorSilk and Revlon Professional in hair color; and Revlon in beauty tools.

Elizabeth Arden – The Elizabeth Arden segment is comprised of the Company’s Elizabeth Arden branded products. The Elizabeth Arden segment markets, distributes and sells fragrances, skin care and color cosmetics primarily to prestige retailers, department and specialty stores, perfumeries, boutiques, e-commerce sites, the mass retail channel, travel retailers and distributors, as well as direct sales to consumers via its Elizabeth Arden branded retail stores and elizabetharden.com e-commerce websites, in the U.S. and internationally, under brands such as Elizabeth Arden Ceramide, Prevage, Eight Hour, SUPERSTART, Visible Difference and Skin Illuminating in the Elizabeth Arden skin care brands; and Elizabeth Arden White Tea, Elizabeth Arden Red Door, Elizabeth Arden 5th Avenue and Elizabeth Arden Green Tea in Elizabeth Arden fragrances.

Portfolio – The Company’s Portfolio segment markets, distributes and sells a comprehensive line of premium, specialty and mass products primarily to the mass retail channel, hair and nail salons and professional salon distributors in the U.S. and internationally and large volume retailers, specialty and department stores under brands such as Almay and SinfulColors in color cosmetics; American Crew in men’s grooming products (which are also sold direct-to-consumer on its americancrew.com website); CND in nail polishes, gel nail color and nail enhancements; Mitchum in anti-perspirant deodorants; and Cutex in nail care products. The Portfolio segment also includes a multi-cultural hair care line consisting of Creme of Nature hair care products, which are sold in both professional salons and in large volume retailers and other retailers, primarily in the U.S.; and a hair color line under the Llongueras brand (licensed from a third party) that is sold in the mass retail channel, large volume retailers and other retailers, primarily in Spain.

Fragrances – The Fragrances segment includes the development, marketing and distribution of certain owned and licensed fragrances, as well as the distribution of prestige fragrance brands owned by third parties. These products are typically sold to retailers in the U.S. and internationally, including prestige retailers, specialty stores, e-commerce sites, the mass retail channel, travel retailers and other international retailers. The owned and licensed fragrances include brands such as Juicy Couture (which are also sold direct-to-consumer on its juicycouturebeauty.com website), Britney Spears, Elizabeth Taylor, Curve, John Varvatos, Christina Aguilera, Giorgio Beverly Hills, Ed Hardy, Charlie, Lucky Brand, Paul Sebastian, Alfred Sung, Jennifer Aniston, Mariah Carey,Halston,Geoffrey Beene and AllSaints.

 

 

 

Three Months Ended September 30,

(Unaudited)

 

 

Net Sales

 

 

As Reported

 

As Reported

(USD millions)

 

2020

 

2019

 

% Change

 

XFX

% Change

 

 

 

 

 

 

 

 

 

Revlon

 

$

166.0

 

 

$

217.3

 

 

(23.6)

%

 

(23.9)

%

Elizabeth Arden

 

106.3

 

123.2

 

(13.7)

%

 

(14.9)

%

Portfolio

 

99.6

 

118.2

 

(15.7)

%

 

(16.2)

%

Fragrances

 

105.2

 

138.1

 

(23.8)

%

 

(24.0)

%

Total

 

$

477.1

 

 

$

596.8

 

 

(20.1)

%

 

(20.5)

%

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

(Unaudited)

 

 

Segment Profit

 

 

As Reported

 

As Reported

(USD millions)

 

2020

 

2019

 

% Change

 

XFX

% Change

 

 

 

 

 

 

 

 

 

Revlon

 

$

13.5

 

 

$

7.3

 

 

84.9

%

 

80.8

%

Elizabeth Arden

 

3.4

 

 

12.5

 

 

(72.8)

%

 

(76.0)

%

Portfolio

 

12.2

 

 

14.4

 

 

(15.3)

%

 

(17.4)

%

Fragrances

 

25.4

 

 

34.2

 

 

(25.7)

%

 

(26.6)

%

Total

 

$

54.5

 

 

$

68.4

 

 

(20.3)

%

 

(22.2)

%

Revlon Segment

Revlon segment net sales in the third quarter of 2020 were $166.0 million, a $51.3 million or 23.6% (23.9% XFX) decrease compared to the prior-year period, with the ongoing COVID-19 pandemic contributing an estimated $50 million ($50 million XFX) to the decrease. The segment’s lower net sales were driven primarily by Revlon color cosmetics, as well as lower international net sales of Revlon-branded professional products, due primarily to the ongoing effects of the COVID-19 pandemic on the mass retail channel and on salon activity. This decrease was partially offset by higher net sales of Revlon-branded beauty tools and hair color products in North America.

Revlon segment profit in the third quarter of 2020 was $13.5 million, compared to $7.3 million in the prior-year period, driven primarily by the segment’s lower brand support, partially offset by lower net sales and lower gross profit margin.

Elizabeth Arden Segment

Elizabeth Arden segment net sales in the third quarter of 2020 were $106.3 million, a $16.9 million or 13.7% (14.9% XFX) decrease compared to the prior-year period, with the ongoing COVID-19 pandemic contributing an estimated $24 million ($25 million XFX) to the decrease. The lower net sales were driven by certain Elizabeth Arden-branded skin care products and color cosmetics in international regions as well as lower net sales of certain Elizabeth Arden-branded fragrances due, in part, to the continuing effects of COVID-19 on foot traffic at department stores and travel retail outlets, partially offset by higher net sales of Ceramide skin care products in North America and strong e-commerce growth.

Elizabeth Arden segment profit in the third quarter of 2020 was $3.4 million, compared to $12.5 million in the prior-year period, primarily due to the segment’s lower net sales and lower gross profit margin, partially offset by lower brand support.

Portfolio Segment

Portfolio segment net sales of $99.6 million in the third quarter of 2020 decreased by $18.6 million, or 15.7% (16.2% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $19 million ($19 million XFX) to the decrease. The decrease in segment net sales was driven primarily by Almay color cosmetics, CND nail products and American Crew men’s grooming products, primarily in North America, due, in part, to the continuing effects of COVID-19 on the mass retail channel and salons, partially offset by higher net sales of Creme of Nature hair care products and Mitchum anti-perspirant deodorants, primarily in North America.

Portfolio segment profit in the third quarter of 2020 was $12.2 million, compared to $14.4 million in the prior-year period, driven by the segment’s lower net sales and lower gross profit margin, partially offset by lower SG&A and brand support expenses as a result of cost reductions achieved through the Company’s initiatives designed to mitigate the adverse impact of COVID-19 on the Company’s operating results, as well as the Revlon 2020 Restructuring Program.

Fragrances Segment

Fragrances segment net sales of $105.2 million in the third quarter of 2020 decreased by $32.9 million, or 23.8% (24.0% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $25 million ($25 million XFX) to the decrease. The segment’s lower net sales were driven primarily by the continuing impacts from COVID-19, especially in the prestige channel, resulting in decreased foot traffic.

Fragrances segment profit in the third quarter of 2020 was $25.4 million, compared to $34.2 million in the prior-year period, primarily as a result of the segment’s lower net sales and lower gross profit margin, partially offset by lower SG&A and brand support expenses, driven by cost reductions achieved through the Company’s initiatives designed to mitigate the adverse impact of COVID-19 on the Company’s operating results, as well as the Revlon 2020 Restructuring Program.

Geographic Net Sales

Overall, As Reported total net sales decreased by 20.1% (or 20.5% XFX) in the third quarter of 2020, compared to the prior-year period, as detailed below by segment for the Company’s North America and International Regions.

 

 

Three Months Ended September 30,

(Unaudited)

(USD millions)

 

2020

As Reported

 

2019

As Reported

 

As Reported

% Change

 

As Reported

XFX

% Change

Net Sales:

 

 

 

 

 

 

 

 

Revlon

 

 

 

 

 

 

 

 

North America

 

$

86.4

 

 

$

100.0

 

 

(13.6)

%

 

(13.7)

%

International

 

79.6

 

 

117.3

 

 

(32.1)

%

 

(32.6)

%

Elizabeth Arden

 

 

 

 

 

 

 

 

North America

 

$

30.5

 

 

$

29.5

 

 

3.4

%

 

3.7

%

International

 

75.8

 

 

93.7

 

 

(19.1)

%

 

(20.8)

%

Portfolio

 

 

 

 

 

 

 

 

North America

 

$

59.9

 

 

$

71.4

 

 

(16.1)

%

 

(15.8)

%

International

 

39.7

 

 

46.8

 

 

(15.2)

%

 

(16.7)

%

Fragrances

 

 

 

 

 

 

 

 

North America

 

$

79.2

 

 

$

98.6

 

 

(19.7)

%

 

(19.6)

%

International

 

26.0

 

 

39.5

 

 

(34.2)

%

 

(34.9)

%

Total Net Sales

 

$

477.1

 

 

$

596.8

 

 

(20.1)

%

 

(20.5)

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total Net Sales Summary

 

 

 

 

 

 

North America

 

$

256.0

 

 

$

299.5

 

 

(14.5)

%

 

(14.4)

%

International

 

221.1

 

 

297.3

 

 

(25.6)

%

 

(26.7)

%

Revlon Segment

In North America, Revlon segment net sales of $86.4 million in the third quarter of 2020 decreased by $13.6 million, or 13.6% (13.7% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $15 million ($15 million XFX) to the decrease. The segment’s lower net sales in North America were primarily driven by lower net sales of Revlon color cosmetics and Revlon ColorSilk hair care products, due to the continuing effects of COVID-19 on the mass retail channel, partially offset by higher net sales of Revlon-branded beauty tools and hair-care products.

In International, Revlon segment net sales of $79.6 million in the third quarter of 2020 decreased by $37.7 million, or 32.1% (32.6% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $35 million ($35 million XFX) to the decrease. The segment’s lower International net sales were driven primarily by lower net sales of Revlon color cosmetics and Revlon-branded professional hair-care products, partially offset by higher net sales of Revlon ColorSilk hair color products, within the Company’s Latin America region and growth in e-commerce net sales.

Elizabeth Arden Segment

In North America, Elizabeth Arden segment net sales were $30.5 million in the third quarter of 2020, an increase of $1.0 million, or 3.4% (3.7% XFX), compared to the prior-year period. COVID-19 impacted net sales by an estimated $1 million ($1 million XFX) versus the prior-year quarter. The improved North America net sales were driven by the segment’s higher net sales of Ceramide skin care products, partially offset by certain other Elizabeth Arden-branded skin care and fragrance products, due primarily to the continuing effects of COVID-19 on foot traffic at department stores and in other retail outlets.

In International, Elizabeth Arden segment net sales of $75.8 million in the third quarter of 2020 decreased by $17.9 million, or 19.1% (20.8% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $23 million ($24 million XFX) to the decrease. The segment’s lower international net sales were driven by lower net sales of Elizabeth Arden-branded skin care products, certain Elizabeth Arden-branded fragrances, primarily within the Company’s EMEA region and continued COVID-19 impacts within the Travel Retail channel.

Portfolio Segment

In North America, Portfolio segment net sales of $59.9 million in the third quarter of 2020 decreased by $11.5 million, or 16.1% (15.8% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $14 million ($14 million XFX) to the decrease. The segment’s lower North America net sales were driven by Almay color cosmetics, CND nail products, American Crew men’s grooming products, driven, primarily, by the continuing effects of COVID-19 on the mass retail channel and on salons. This decrease was partially offset by higher net sales of Creme of Nature products, Mitchum antiperspirant deodorants and Cutex nail products.

In International, Portfolio segment net sales of $39.7 million in the third quarter of 2020 decreased by $7.1 million, or 15.2% (16.7% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $5 million ($5 million XFX) to the decrease. The segment’s lower International net sales were driven primarily by lower net sales of local and regional brands, CND nail products, American Crew men’s grooming products and Almay color cosmetics, primarily in the Company’s EMEA region, largely attributable to COVID-19’s continuing adverse effects on consumer foot traffic in salons and in the mass retail channel.

Fragrances Segment

In North America, Fragrances segment net sales of $79.2 million in the third quarter of 2020 decreased by $19.4 million, or 19.7% (19.6% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $16 million ($16 million XFX) to the decrease. The segment’s lower net sales in North America compared to the prior year quarter were driven primarily by the continuing impacts from COVID-19, especially in the prestige channel, resulting in decreased foot traffic.

In International, Fragrances segment net sales of $26.0 million in the third quarter of 2020 decreased by $13.5 million, or 34.2% (or 34.9% XFX), compared to the prior-year period, with COVID-19 contributing an estimated $9 million ($9 million XFX) to the decrease. The segment’s lower international net sales were due to lower net sales of certain licensed fragrances primarily in the Company’s EMEA region, due to the continuing impacts from COVID-19, resulting in decreased foot traffic.

Cash Flow

Net cash used in operating activities in the first nine months of 2020 was $256.9 million, compared to $166.8 million in the prior-year period. The increase in cash usage was driven primarily by the COVID-related lower net sales. Free cash flow(a) used in the first nine months of 2020 was $264.3 million, compared to $186.8 million used in the prior-year period. The increase in free cash flow usage was driven by higher operating cash flow usage, due in part to COVID-19’s ongoing adverse impacts on the business, partially offset by lower capital expenditures.

Liquidity Update

As of September 30, 2020, the Company had approximately $340.4 million of available liquidity, consisting of $268.3 million of unrestricted cash and cash equivalents, as well as $52.6 million in available borrowing capacity under the Product Corporation’s Amended 2016 Revolving Credit Facility (which had $291.9 million drawn as of such date) and $30.0 million in available borrowing capacity under the 2020 Restated Line of Credit (which was undrawn as of such date), less float of approximately $10.5 million.

5.75% Senior Notes Exchange Offer Update

As of 11:59 p.m., New York City time, on Tuesday, November 10, 2020, approximately $236 million aggregate principal amount of the Notes (or approximately 68.8% of the aggregate outstanding principal amount of such series of Notes) had been validly tendered into the Exchange Offer and Consent Solicitation and not withdrawn.

All conditions precedent to the consummation of the Exchange Offer and Consent Solicitation have been satisfied, including the minimum liquidity requirement of $175 million, and settlement is expected to occur on Friday, November 13, 2020, subject to customary closing conditions.

Third Quarter 2020 Results Conference Call

The Company will host a conference call with members of the investment community today, November 12, 2020, at 5:00 P.M. EST to discuss its third quarter 2020 financial results. Access to the call is available to the public at www.revloninc.com.

Footnotes to Press Release

(a) Non-GAAP Financial Measures: EBITDA; Adjusted EBITDA; Adjusted net sales; Adjusted operating loss/income; Adjusted net income/loss; Adjusted gross profit; Adjusted gross profit margin; Adjusted diluted loss per common share and free cash flow (together, the “Non-GAAP Measures”) are non-GAAP financial measures. See the reconciliations of such Non-GAAP Measures to their most directly comparable GAAP measures in the accompanying financial tables, to the extent not otherwise directly reconciled in the Company’s financial results.

The Company defines EBITDA as income from continuing operations before interest, taxes, depreciation, amortization, gains/losses on foreign currency fluctuations, gains/losses on the early extinguishment of debt and miscellaneous expenses (the foregoing being the “EBITDA Exclusions”). The Company presents Adjusted EBITDA to exclude the EBITDA Exclusions, as well as the impact of non-cash stock-based compensation expense and certain other non-operating items that are not directly attributable to the Company’s underlying operating performance (the “Non-Operating Items”). The following table identifies the Non-Operating Items excluded in the presentation of Adjusted EBITDA for all periods:

 

(USD millions)

Q3 2020

Q3 2019

Net Loss Adjustments to EBITDA

 

(Unaudited)

Non-Operating Items:

 

Non-cash stock-based compensation expense

$

5.1

 

$

3.9

 

Restructuring and related charges

4.5

 

5.4

 

Acquisition, integration and divestiture costs

0.9

 

0.1

 

Gain on divested assets

(1.1)

 

 

Financial control remediation and sustainability actions and related charges

0.7

 

3.4

 

COVID-19 charges

9.7

 

 

Capital structure and related charges

9.3

 

 

Adjusted net loss and adjusted diluted loss per common share exclude the after-tax impact of the Non-Operating Items from As Reported net loss.

The Company excludes the EBITDA Exclusions and Non-Operating Items, as applicable, in calculating the Non-GAAP Measures because the Company’s management believes that some of these items may not occur in certain periods, the amounts recognized can vary significantly from period to period and/or these items do not facilitate an understanding of the Company’s underlying operating performance.

Free cash flow is defined as net cash provided by/used in operating activities, less capital expenditures for property, plant and equipment. Free cash flow excludes proceeds on sale of discontinued operations. Free cash flow does not represent the residual cash flow available for discretionary expenditures, as it excludes certain expenditures such as mandatory debt service requirements, which for the Company are significant.

The Company’s management uses the Non-GAAP Measures as operating performance measures, and in the case of free cash flow, as a liquidity measure (in conjunction with GAAP financial measures), as an integral part of its reporting and planning processes and to, among other things: (i) monitor and evaluate the performance of the Company’s business operations, financial performance and overall liquidity; (ii) facilitate management’s internal comparisons of the Company’s historical operating performance of its business operations; (iii) facilitate management’s external comparisons of the results of its overall business to the historical operating performance of other companies that may have different capital structures and debt levels; (iv) review and assess the operating performance of the Company’s management team and, together with other operational objectives, as a measure in evaluating employee compensation, including bonuses and other incentive compensation; (v) analyze and evaluate financial and strategic planning decisions regarding future operating investments; and (vi) plan for and prepare future annual operating budgets and determine appropriate levels of operating investments.

Management believes that the Non-GAAP Measures are useful to investors to provide them with disclosures of the Company’s operating results on the same basis as that used by management. Management believes that the Non-GAAP Measures provide useful information to investors about the performance of the Company’s overall business because such measures eliminate the effects of certain charges that are not directly attributable to the Company’s underlying operating performance. Additionally, management believes that providing the Non-GAAP Measures enhances the comparability for investors in assessing the Company’s financial reporting. Management believes that free cash flow is useful for investors because it provides them with an important perspective on the cash available for debt service and other strategic measures, after making necessary capital investments in property and equipment to support the Company’s ongoing business operations, and provides them with the same measures that management uses as the basis for making resource allocation decisions.

Accordingly, the Company believes that the presentation of the Non-GAAP Measures, when used in conjunction with GAAP financial measures, are useful financial analytical measures that are used by management, as described above, and therefore can assist investors in assessing the Company’s financial condition, operating performance and underlying strength. The Non-GAAP Measures should not be considered in isolation or as a substitute for their respective most directly comparable As Reported financial measures prepared in accordance with GAAP, such as net income/loss, operating income/loss, diluted earnings/loss per share or net cash provided by (used in) operating activities. Other companies may define such non-GAAP measures differently. Also, while EBITDA and Adjusted EBITDA, as used in this release, are defined differently than Adjusted EBITDA for the Company’s credit agreements and indentures, certain financial covenants in its borrowing arrangements are tied to similar financial measures. These non-GAAP financial measures should be read in conjunction with the Company’s financial statements and related footnotes filed with the SEC.

(b) Segment profit is defined as income from continuing operations for each of the Company’s Revlon, Elizabeth Arden, Portfolio and Fragrances segments, excluding the EBITDA Exclusions. Segment profit also excludes the impact of certain items that are not directly attributable to the segments’ underlying operating performance, including the impact of the Non-Operating Items noted above in footnote (a). The Company does not have any material inter-segment sales.

FORWARD-LOOKING STATEMENTS

Statements made in this press release, which are not historical facts, are forward-looking and are provided pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date they are made and the Company undertakes no obligation to publicly update any forward-looking statement, whether to reflect actual results of operations; changes in financial condition; changes in general U.S. or international economic or industry conditions and/or conditions in the Company’s reportable segments; changes in estimates, expectations or assumptions; or other circumstances, conditions, developments and/or events arising after the issuance of this press release, except for the Company’s ongoing obligations under the U.S. federal securities laws. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on preliminary or potentially inaccurate estimates and assumptions that could cause actual results to differ materially from those expected or implied by the estimated financial information. Such forward-looking statements include, among other things: (i) the Company’s expectations to remain diligent in managing its cost base to reduce COVID-19’s impact on the Company’s profitability; (ii) the Company’s expectations that, based on the aggregate principal amount of 5.75% Senior Notes tendered into the Company’s pending Exchange Offer, it will close that transaction later this week, giving the Company the additional runway needed to further execute on its business strategy, including investing in the brands and markets where the Company has scale, and growing its e-commerce business; and (iii) the Company’s belief that while it still has challenges to face – namely the ongoing impact of the COVID-19 pandemic –it has the right long-term strategy in place and will continue to execute against i. Actual results may differ materially from the Company’s forward-looking statements for a number of reasons, including as a result of the risks and other items described in Revlon’s filings with the SEC, including, without limitation, in Revlon’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K and amendments thereto, if any, filed with the SEC during 2019 and 2020 (which may be viewed on the SEC’s website at http://www.sec.gov or on Revlon, Inc.’s website at http://www.revloninc.com). Additional important factors that could cause actual results to differ materially from those indicated by the Company’s forward-looking statements include: (i) difficulties, delays or unanticipated costs or charges or less than expected cost reductions and other benefits resulting from the Company’s cost reduction initiatives and/or restructuring activities, such as in connection with the Revlon 2020 Restructuring Program, higher than anticipated restructuring charges and/or payments and/or changes in the expected timing of such charges and/or payments; and/or less than expected additional sources of liquidity from such initiatives; (ii) difficulties or delays that could affect the Company’s ability to consummate the Exchange Offer and/or redeem the 5.75% Senior Notes, in whole or in part, such as due to the Company’s respective businesses experiencing ongoing COVID-19 related disruptions or other factors, such as lower than expected operating revenues, cash on hand and/or other permissible borrowings or generated from cost reductions resulting from the implementation of the Revlon 2020 Restructuring Program and/or other cost control initiatives and/or difficulties, delays in or less than expected results from the Company’s efforts to execute on its business strategies to drive its future success and growth, including, without limitation: (1) less than effective new product development and innovation, less than expected acceptance of its new products and innovations by the Company’s consumers and/or customers in one or more of its segments and/or less than expected levels of execution vis-à-vis its new product launches with its customers in one or more of its segments or regions, in each case whether attributable to COVID-19 or otherwise; (2) less than expected levels of advertising, promotional and/or marketing activities for its new product launches, less than expected acceptance of its advertising, promotional, pricing and/or marketing plans and/or brand communication by consumers and/or customers in one or more of its segments, less than expected investment in advertising, promotional and/or marketing activities or greater than expected competitive investment, in each case whether attributable to COVID-19 or otherwise; and/or (3) difficulties or disruptions impacting the Company’s ability to ensure availability of its products where consumers shop, both in-store and increasingly online; and/or (iii) the Company’s inability, in whole or in part, to continue to execute its business strategy, such as due to unanticipated circumstances or results affecting the Company’s financial performance and or sales growth, including: greater than anticipated levels of consumers choosing to purchase their beauty products through e-commerce and other social media channels and/or greater than anticipated declines in the brick-and-mortar retail channel, or either of those conditions occurring at a rate faster than anticipated; the Company’s inability to address the pace and impact of the new commercial landscape, such as its inability to enhance its e-commerce and social media capabilities and/or increase its penetration of e-commerce and social media channels; the Company’s inability to drive a successful long-term omni-channel strategy and significantly increase its e-commerce penetration; difficulties, delays and/or the Company’s inability to (in whole or in part) develop and implement effective content to enhance its online retail position, improve its consumer engagement across social media platforms and/or transform its technology and data to support efficient management of its digital infrastructure; the Company incurring greater than anticipated levels of expenses and/or debt to facilitate the foregoing objectives, which could result in, among other things, less than anticipated revenues and/or profitability; decreased consumer spending in response to weak economic conditions or weakness in the consumption of beauty products in one or more of the Company’s segments, whether attributable to COVID-19 or otherwise; adverse changes in tariffs, foreign currency exchange rates, foreign currency controls and/or government-mandated pricing controls; decreased sales of the Company’s products as a result of increased competitive activities by the Company’s competitors; decreased performance by third-party suppliers, whether due to COVID-19, shortages of raw materials or otherwise; and/or supply disruptions at the Company’s manufacturing facilities, whether attributable to COVID-19 or otherwise; changes in consumer preferences, such as reduced consumer demand for the Company’s color cosmetics and other current products, including new product launches; changes in consumer purchasing habits, including with respect to retailer preferences and/or among sales channels, such as due to the continuing consumption declines in core beauty categories in the mass retail channel in North America, whether attributable to COVID-19 or otherwise; lower than expected customer acceptance or consumer acceptance of, or less than anticipated results from, the Company’s existing or new products, whether attributable to COVID-19 or otherwise; higher than expected retail store closures in the brick-and-mortar channels where the Company sells its products, as consumers continue to shift purchases to online and e-commerce channels, whether attributable to COVID-19 or otherwise; higher than expected purchases of permanent displays, capital expenditures, debt service payments and costs, cash tax payments, pension and other post-retirement plan contributions, payments in connection with the Company’s restructuring programs (such as the Revlon 2020 Restructuring Program), severance not otherwise included in the Company’s restructuring programs, business and/or brand acquisitions (including, without limitation, through licensing transactions), if any, debt and/or equity repurchases, if any, costs related to litigation, discontinuing non-core business lines and/or entering and/or exiting certain territories and/or channels of trade, advertising, promotional and marketing activities or for sales returns related to any reduction of space by the Company’s customers, product discontinuances or otherwise or lower than expected results from the Company’s advertising, promotional, pricing and/or marketing plans, whether attributable to COVID-19 or otherwise; decreased sales of the Company’s existing or new products, whether attributable to COVID-19 or otherwise; actions by the Company’s customers, such as greater than expected inventory management and/or de-stocking, and greater than anticipated space reconfigurations or reductions in display space and/or product discontinuances or a greater than expected impact from pricing, marketing, advertising and/or promotional strategies by the Company’s customers, whether attributable to COVID-19 or otherwise; and changes in the competitive environment and actions by the Company’s competitors, including, among other things, business combinations, technological breakthroughs, implementation of new pricing strategies, new product offerings, increased advertising, promotional and marketing spending and advertising, promotional and/or marketing successes by competitors. Factors other than those referred to above could also cause Revlon’s results to differ materially from expected results. Additionally, the business and financial materials and any other statement or disclosure on, or made available through, Revlon’s website or other websites referenced herein shall not be incorporated by reference into this press release.

 

REVLON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(dollars in millions, except share and per share amounts)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2020

 

2019

 

2020

 

2019

 

(Unaudited)

 

(Unaudited)

 

 

 

 

 

 

 

 

Net sales

$

477.1

 

 

$

596.8

 

 

$

1,277.7

 

 

$

1,720.2

 

Cost of sales

234.3

 

 

269.0

 

 

600.7

 

 

750.7

 

Gross profit

242.8

 

 

327.8

 

 

677.0

 

 

969.5

 

Selling, general and administrative expenses

253.4

 

 

308.1

 

 

739.1

 

 

973.2

 

Acquisition, integration and divestiture costs

0.9

 

 

0.1

 

 

4.2

 

 

0.7

 

Restructuring charges and other, net

(0.7

)

 

2.9

 

 

44.8

 

 

11.6

 

Impairment charges

 

 

 

 

144.1

 

 

 

Gain on divested assets

(1.1

)

 

 

 

(0.5

)

 

 

Operating (loss) income

(9.7

)

 

16.7

 

 

(254.7

)

 

(16.0

)

 

 

 

 

 

 

 

 

Other expenses:

 

 

 

 

 

 

 

Interest expense

68.7

 

 

50.2

 

 

178.0

 

 

145.7

 

Amortization of debt issuance costs

7.8

 

 

3.7

 

 

17.8

 

 

10.4

 

Gain on early extinguishment of debt, net

(31.2

)

 

 

 

(43.1

)

 

 

Foreign currency (gains) losses, net

(9.8

)

 

7.6

 

 

9.1

 

 

9.0

 

Miscellaneous, net

(2.6

)

 

1.7

 

 

13.9

 

 

7.6

 

Other expenses

32.9

 

 

63.2

 

 

175.7

 

 

172.7

 

 

 

 

 

 

 

 

 

Loss from continuing operations before income taxes

(42.6

)

 

(46.5

)

 

(430.4

)

 

(188.7

)

Provision for (benefit from) income taxes

1.9

 

 

(2.1

)

 

(45.2

)

 

(3.2

)

Loss from continuing operations, net of taxes

(44.5

)

 

(44.4

)

 

(385.2

)

 

(185.5

)

(Loss) income from discontinued operations, net of taxes

 

 

(0.3

)

 

 

 

2.0

 

Net loss

$

(44.5

)

 

$

(44.7

)

 

$

(385.2

)

 

$

(183.5

)

 

 

 

 

 

 

 

 

Other comprehensive income (loss):

 

 

 

 

 

 

 

Foreign currency translation adjustments

2.2

 

 

(1.8

)

 

7.3

 

 

(0.5

)

Amortization of pension related costs, net of tax

2.8

 

 

2.3

 

 

9.3

 

 

7.2

 

Other comprehensive (loss) income, net

5.0

 

 

0.5

 

 

16.6

 

 

6.7

 

Total comprehensive loss

$

(39.5

)

 

$

(44.2

)

 

$

(368.6

)

 

$

(176.8

)

 

 

 

 

 

 

 

 

Basic and Diluted (loss) earnings per common share:

 

 

 

 

 

 

 

Continuing operations

$

(0.83

)

 

$

(0.84

)

 

$

(7.22

)

 

$

(3.50

)

Discontinued operations

 

 

 

 

 

 

0.04

 

Net loss

$

(0.83

)

 

$

(0.84

)

 

$

(7.22

)

 

$

(3.46

)

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding:

 

 

 

 

 

 

 

Basic

53,476,354

 

 

53,129,004

 

 

53,371,986

 

 

53,057,154

 

Diluted

53,476,354

 

 

53,129,004

 

 

53,371,986

 

 

53,057,154

 

 

REVLON, INC. AND SUBSIDIARIES

CONSOLIDATED CONDENSED BALANCE SHEETS

(dollars in millions)

 

 

 

 

 

September 30,

 

December 31,

 

2020

 

2019

ASSETS

(Unaudited)

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

268.3

 

 

$

104.3

 

Trade receivables, net

340.8

 

 

423.4

 

Inventories, net

525.5

 

 

448.4

 

Prepaid expenses and other current assets

140.8

 

 

135.3

 

Total current assets

1,275.4

 

 

1,111.4

 

Property, plant and equipment, net

355.8

 

 

408.6

 

Deferred income taxes

230.5

 

 

175.1

 

Goodwill

563.2

 

 

673.7

 

Intangible assets, net

435.9

 

 

490.7

 

Other assets

112.5

 

 

121.1

 

Total assets

$

2,973.3

 

 

$

2,980.6

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS’ DEFICIENCY

 

 

 

Current liabilities:

 

 

 

Short-term borrowings

$

2.0

 

 

$

2.2

 

Current portion of long-term debt

704.5

 

 

288.0

 

Accounts payable

219.9

 

 

251.8

 

Accrued expenses and other current liabilities

387.9

 

 

414.9

 

Total current liabilities

1,314.3

 

 

956.9

 

Long-term debt

2,926.5

 

 

2,906.2

 

Long-term pension and other post-retirement plan liabilities

166.7

 

 

181.2

 

Other long-term liabilities

148.7

 

 

157.5

 

Total stockholders’ deficiency

(1,582.9

)

 

(1,221.2

)

Total liabilities and stockholders’ deficiency

$

2,973.3

 

 

$

2,980.6

 

 

REVLON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(dollars in millions)

 

Nine Months Ended

 

September 30,

 

2020

 

2019

CASH FLOWS FROM OPERATING ACTIVITIES:

(Unaudited)

Net loss

$

(385.2

)

 

$

(183.5

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

Depreciation and amortization

108.3

 

 

124.6

 

Foreign currency losses from re-measurement

9.1

 

 

9.0

 

Amortization of debt discount

1.3

 

 

1.2

 

Stock-based compensation amortization

8.6

 

 

7.7

 

Impairment charges

144.1

 

 

 

Benefit from deferred income taxes

(54.4

)

 

(19.0

)

Amortization of debt issuance costs

17.8

 

 

10.4

 

Gain on divested assets

(0.5

)

 

 

Pension and other post-retirement cost

4.2

 

 

6.3

 

Gain on early extinguishment of debt, net

(43.1

)

 

 

Paid-in-kind interest accrued on the 2020 Brandco Facilities

6.2

 

 

 

Change in assets and liabilities:

 

 

 

Decrease (increase) in trade receivables

78.0

 

 

(30.5

)

Increase in inventories

(79.4

)

 

(4.9

)

Increase in prepaid expenses and other current assets

(1.7

)

 

(5.5

)

(Decrease) Increase in accounts payable

(27.8

)

 

9.1

 

Decrease in accrued expenses and other current liabilities

(25.2

)

 

(81.0

)

Pension and other post-retirement plan contributions

(7.5

)

 

(7.8

)

Purchases of permanent displays

(16.5

)

 

(28.4

)

Other, net

6.8

 

 

25.5

 

Net cash used in operating activities

(256.9

)

 

(166.8

)

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

Capital expenditures

(7.4

)

 

(20.0

)

Net cash used in investing activities

(7.4

)

 

(20.0

)

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

Net decrease in short-term borrowings and overdraft

(0.7

)

 

(22.4

)

Borrowings under the 2020 BrandCo Facilities

880.0

 

 

 

Repurchase of the 5.75% Senior Notes

(114.1

)

 

 

Net borrowings under the Amended 2016 Revolving Credit Facility

19.5

 

 

13.4

 

Repayment of the 2019 Term Loan Facility

(200.0

)

 

200.0

 

Repayment under the 2018 Foreign Asset-Based Term Loan

(31.4

)

 

 

Repayments under the 2016 Term Loan Facility

(9.2

)

 

(13.5

)

Payment of financing costs

(108.3

)

 

(13.4

)

Tax withholdings related to net share settlements of restricted stock and RSUs

(1.6

)

 

(1.6

)

Other financing activities

(0.3

)

 

(0.9

)

Net cash provided by financing activities

433.9

 

 

161.6

 

Effect of exchange rate changes on cash, cash equivalents and restricted cash

(0.4

)

 

(1.4

)

Net increase (decrease) in cash, cash equivalents and restricted cash

169.2

 

 

(26.6

)

Cash, cash equivalents and restricted cash at beginning of period

104.5

 

 

87.5

 

Cash, cash equivalents and restricted cash at end of period

$

273.7

 

 

$

60.9

 

Supplemental schedule of cash flow information:

 

 

 

Cash paid during the period for:

 

 

 

Interest

$

182.2

 

 

$

157.9

 

Income taxes, net of refunds

12.6

 

 

6.9

 

Supplemental schedule of non-cash investing and financing activities:

 

 

 

Non-cash roll-up of participating lenders from the 2016 Term Loan Facility to the 2020 Brandco Facilities

$

846.0

 

 

$

 

Paid-in-kind debt issuance costs capitalized to the 2020 Brandco Facilities

29.1

 

 

 

 

REVLON, INC. AND SUBSIDIARIES

EBITDA AND ADJUSTED EBITDA RECONCILIATION

(dollars in millions)

 

 

 

 

 

Three Months Ended September 30,

 

2020

 

2019

 

(Unaudited)

Reconciliation to net loss:

 

 

 

Net loss

$

(44.5

)

 

$

(44.7

)

Income (loss) from discontinued operations, net of taxes

 

 

(0.3

)

Loss from continuing operations, net of taxes

(44.5

)

 

(44.4

)

 

 

 

 

Interest expense, net

68.7

 

 

50.2

 

Amortization of debt issuance costs

7.8

 

 

3.7

 

Loss on early extinguishment of debt

(31.2

)

 

 

Foreign currency (gains) losses, net

(9.8

)

 

7.6

 

Provision for (benefit from) income taxes

1.9

 

 

(2.1

)

Depreciation and amortization

35.1

 

 

38.9

 

Miscellaneous, net

(2.6

)

 

1.7

 

EBITDA

$

25.4

 

 

$

55.6

 

Non-operating items:

 

 

 

Non-cash stock-based compensation expense

5.1

 

 

3.9

 

Restructuring and related charges

4.5

 

 

5.4

 

Acquisition, integration and divestiture costs

0.9

 

 

0.1

 

Gain on divested assets

(1.1

)

 

 

Financial control remediation and sustainability actions and related charges

0.7

 

 

3.4

 

COVID-19 charges

9.7

 

 

 

Capital structure and related charges

9.3

 

 

 

Adjusted EBITDA

$

54.5

 

 

$

68.4

 

 

 

 

 

 

Nine Months Ended September 30,

 

2020

 

2019

 

(Unaudited)

 

 

 

 

Reconciliation to net loss:

 

 

 

Net loss

$

(385.2

)

 

$

(183.5

)

Income (loss) from discontinued operations, net of taxes

 

 

2.0

 

Loss from continuing operations, net of taxes

(385.2

)

 

(185.5

)

Interest expense

178.0

 

 

145.7

 

Amortization of debt issuance costs

17.8

 

 

10.4

 

Loss on early extinguishment of debt

(43.1

)

 

 

Foreign currency losses, net

9.1

 

 

9.0

 

Benefit from income taxes

(45.2

)

 

(3.2

)

Depreciation and amortization

108.3

 

 

124.6

 

Miscellaneous, net

13.9

 

 

7.6

 

EBITDA

$

(146.4

)

 

$

108.6

 

Non-operating items:

 

 

 

Non-cash stock-based compensation expense

8.6

 

 

7.7

 

Restructuring and related charges

61.2

 

 

27.4

 

Acquisition, integration and divestiture costs

4.2

 

 

0.7

 

Gain on divested assets

(0.5

)

 

 

Financial control remediation and sustainability actions and related charges

8.5

 

 

9.8

 

Impairment charges

144.1

 

 

 

Excessive coupon redemption

4.2

 

 

 

COVID-19 charges

35.1

 

 

 

Capital structure and related charges

9.3

 

 

 

Adjusted EBITDA

$

128.3

 

 

$

154.2

 

 

REVLON, INC. AND SUBSIDIARIES

SEGMENT PROFIT, ADJUSTED EBITDA AND ADJUSTED OPERATING LOSS RECONCILIATION

(dollars in millions)

 

 

 

 

 

 

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

2020

 

2019

 

2020

 

2019

 

(Unaudited)

 

(Unaudited)

Segment Profit:

 

 

 

 

 

 

 

Revlon

$

13.5

 

 

$

7.3

 

 

$

41.4

 

 

$

58.5

 

Elizabeth Arden

3.4

 

 

12.5

 

 

18.4

 

 

17.1

 

Portfolio

12.2

 

 

14.4

 

 

33.9

 

 

25.0

 

Fragrances

25.4

 

 

34.2

 

 

34.6

 

 

53.6

 

Total Segment Profit/Adjusted EBITDA

$

54.5

 

 

$

68.4

 

 

$

128.3

 

 

$

154.2

 

 

 

 

 

 

 

 

 

Reconciliation to loss from continuing operations before income taxes:

 

 

 

 

 

 

 

Loss from continuing operations before income taxes

$

(42.6

)

 

$

(46.5

)

 

$

(430.4

)

 

$

(188.7

)

Interest expense

68.7

 

 

50.2

 

 

178.0

 

 

145.7

 

Amortization of debt issuance costs

7.8

 

 

3.7

 

 

17.8

 

 

10.4

 

Loss on early extinguishment of debt

(31.2

)

 

 

 

(43.1

)

 

 

Foreign currency (gains) losses, net

(9.8

)

 

7.6

 

 

9.1

 

 

9.0

 

Miscellaneous, net

(2.6

)

 

1.7

 

 

13.9

 

 

7.6

 

Operating loss

(9.7

)

 

16.7

 

 

(254.7

)

 

(16.0

)

 

 

 

 

 

 

 

 

Non-operating items:

 

 

 

 

 

 

 

Restructuring and related charges

4.5

 

 

5.4

 

 

61.2

 

 

27.4

 

Acquisition, integration and divestiture costs

0.9

 

 

0.1

 

 

4.2

 

 

0.7

 

Gain on divested assets

(1.1

)

 

 

 

(0.5

)

 

 

Financial control remediation and sustainability actions and related charges

0.7

 

 

3.4

 

 

8.5

 

 

9.8

 

Impairment charges

 

 

 

 

144.1

 

 

 

Excessive coupon redemption

 

 

 

 

4.2

 

 

 

COVID-19 charges

9.7

 

 

 

 

35.1

 

 

 

Capital structure and related charges

9.3

 

 

 

 

9.3

 

 

 

Adjusted Operating loss

14.3

 

 

25.6

 

 

11.4

 

 

21.9

 

Non-cash stock-based compensation expense

5.1

 

 

3.9

 

 

8.6

 

 

7.7

 

Depreciation and amortization

35.1

 

 

38.9

 

 

108.3

 

 

124.6

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

$

54.5

 

 

$

68.4

 

 

$

128.3

 

 

$

154.2

 

 
REVLON, INC. AND SUBSIDIARIES

ADJUSTED NET SALES RECONCILIATION

(dollars in millions)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30,

 

2020

 

2019

 

2020

 

2019

 

(Unaudited)

 

(Unaudited)

Segment Net Sales

 

 

 

 

 

 

 

Revlon

$

166.0

 

 

$

217.3

 

 

$

482.8

 

 

$

716.1

 

Elizabeth Arden

106.3

 

 

123.2

 

 

282.4

 

 

352.0

 

Portfolio

99.6

 

 

118.2

 

 

298.1

 

 

354.1

 

Fragrances

105.2

 

 

138.1

 

 

214.4

 

 

298.0

 

Total Segment Net Sales

$

477.1

 

 

$

596.8

 

 

$

1,277.7

 

 

$

1,720.2

 

 

 

 

 

 

 

 

 

Non-operating items:

 

 

 

 

 

 

 

Excessive coupon redemption

 

 

 

 

4.2

 

 

 

Total Adjusted Net Sales

$

477.1

 

 

$

596.8

 

 

$

1,281.9

 

 

$

1,720.2

 

 

REVLON, INC. AND SUBSIDIARIES

ADJUSTED GROSS PROFIT RECONCILIATION

(dollars in millions)

 

 

 

 

 

 

 

 

 

Three Months Ended

September 30,

 

Nine Months Ended

September 30

 

2020

 

2019

 

2020

 

2019

 

(Unaudited)

 

(Unaudited)

Gross Profit

$

242.8

 

 

$

327.8

 

 

$

677.0

 

 

$

969.5

 

Non-operating items:

 

 

 

 

 

 

 

COVID-19 charges

5.6

 

 

 

 

27.0

 

 

 

Excessive coupon redemption

 

 

 

 

4.2

 

 

 

Financial control remediation and sustainability actions and related charges

 

 

 

 

6.1

 

 

 

Restructuring and related charges

 

 

1.2

 

 

 

 

4.2

 

Adjusted Gross Profit

$

248.4

 

 

$

329.0

 

 

$

714.3

 

 

$

973.7

 

 

 

 

 

 

 

 

 

REVLON, INC. AND SUBSIDIARIES

ADJUSTED NET INCOME (LOSS) AND ADJUSTED DILUTED INCOME (LOSS) PER SHARE RECONCILIATION

(dollars in millions, except share and per share amounts)

 

 

 

 

 

Three Months Ended

September 30,

 

2020

 

2019

 

(Unaudited)

 

 

 

 

Reconciliation to net loss and diluted loss per share:

 

 

 

Net loss

$

(44.5

)

 

$

(44.7

)

 

 

 

 

Non-operating items (after-tax):

 

 

 

Restructuring and related charges

3.8

 

 

4.6

 

Acquisition, integration and divestiture costs

0.7

 

 

 

Gain on divested assets

(0.9

)

 

 

Financial control remediation and sustainability actions and related charges

0.5

 

 

2.6

 

COVID-19 charges

2.3

 

 

 

Capital structure and related charges

7.3

 

 

 

 

 

 

 

Adjusted net loss

$

(30.8

)

 

$

(37.5

)

 

 

 

 

Net loss:

 

 

 

Diluted loss per common share

(0.83

)

 

(0.84

)

Adjustment to diluted loss per common share

0.25

 

 

0.13

 

Adjusted diluted loss per common share

$

(0.58

)

 

$

(0.71

)

 

 

 

 

U.S. GAAP weighted average number of common shares outstanding:

 

 

 

Diluted

53,476,354

 

 

53,129,004

 

 

 

 

 

 

 

 

 

 

Nine Months Ended

September 30,

 

2020

 

2019

 

(Unaudited)

 

 

 

 

Reconciliation to net loss and diluted loss per share:

 

 

 

Net loss

$

(385.2

)

 

$

(183.5

)

 

 

 

 

Non-operating items (after-tax):

 

 

 

Restructuring and related charges

48.5

 

 

21.6

 

Acquisition, integration and divestiture costs

3.3

 

 

0.5

 

Gain on divested assets

(0.4

)

 

 

Financial control remediation and sustainability actions and related charges

6.4

 

 

7.5

 

Impairment charges

130.7

 

 

 

Excessive coupon redemption

3.3

 

 

 

COVID-19 charges

7.6

 

 

 

Capital structure and related charges

7.3

 

 

 

 

 

 

 

Adjusted net loss

$

(178.5

)

 

$

(153.9

)

 

 

 

 

Net loss:

 

 

 

Diluted loss per common share

(7.22

)

 

(3.46

)

Adjustment to diluted loss per common share

3.88

 

 

0.56

 

Adjusted diluted loss per common share

$

(3.34

)

 

$

(2.90

)

 

 

 

 

U.S. GAAP weighted average number of common shares outstanding:

 

 

 

Diluted

53,371,986

 

 

53,057,154

 

 

 

 

 

REVLON, INC. AND SUBSIDIARIES

FREE CASH FLOW RECONCILIATION

(dollars in millions)

 

 

 

 

 

Nine Months Ended

September 30,

 

2020

 

2019

 

(Unaudited)

 

 

 

 

Reconciliation to net cash used in operating activities:

 

 

 

Net cash used in operating activities

$

(256.9

)

 

$

(166.8

)

Less capital expenditures

(7.4

)

 

(20.0

)

 

 

 

 

Free cash flow

$

(264.3

)

 

$

(186.8

)

 

Investor Relations:

212-527-4040 or [email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Cosmetics Retail Online Retail Fashion

MEDIA:

Logo
Logo